<DOC>
	<DOC>NCT00266630</DOC>
	<brief_summary>The efficacy and safety of the extended treatment to patients with most recent episode manic or mixed who completed previous double blind study (F1D-JE-BMAC [Study BMAC]) will be examined.</brief_summary>
	<brief_title>Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Enrolled in and completed Study BMAC (NCT00129220), or those who discontinued Study BMAC at Visit 4 or Visit 5 due to lack of efficacy and for whom the Young Mania Rating Scale (YMRS) total score at the time of discontinuation was not lower than that at baseline of Study BMAC Are diagnosed as "294.4x Bipolar I Disorder, Most Recent Episode Manic" or "296.6x Bipolar I Disorder, Most Recent Episode Mixed," as determined by the MiniInternational Neuropsychiatric Interview (MINI) Have a diagnosis of diabetes mellitus Significant protocol deviation in Study BMAC The actual date of the final visit of Study BMAC is 4 days or more later than the scheduled date of first visit in Study BMEX</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>